TF and neoplasm: DELFI-TF and ddPCR tumor fractions were lower in patients who never had disease progression at any time point during the CAIRO5 trial (never-progressors) than in patients who experienced progressive disease at some point during treatment (ever-progressors), while imaging analyses could not distinguish between these groups (Supplementary Fig. 7).